Crossmark

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

Crossref DOI link: https://doi.org/10.1007/s00280-017-3445-z

Published Online: 2017-10-25

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sakai, Daisuke

Chung, Hyun Cheol

Oh, Do-Youn

Park, Se Hoon

Kadowaki, Shigenori

Kim, Yeul Hong

Tsuji, Akihito

Komatsu, Yoshito

Kang, Yoon-Koo

Uenaka, Kazunori

Wijayawardana, Sameera R.

Wacheck, Volker

Wang, Xuejing

Yamamura, Ayuko

Doi, Toshihiko
License Information

License valid from 2017-10-25